New approaches to adjuvant chemotherapy for breast cancer

Pharmacotherapy

Volumn 16, Issue 3 II, 1996, Pages 885-935

  Hudis, Clifford ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3142523587     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 33 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339(parts 1 and 2): 1-15, 71-85.
2. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-70.
3. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
4. Wood W, Budman D, Korzun A. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
5. Dimitrov N, Andersen S, Fisher B, et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: findings from NSABP B-22 [abstr 58]. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology, May 14-17, 1994, Dallas, Texas. Proc Am Soc Clin Oncol 1994;13:64.
6. Skipper HE. Laboratory models: the historical perspective. Cancer Treatment Rep 1986;70:3-7.
7. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-71.
8. Bonadonna G, Zambette M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 1995;273:542-7.
9. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992:10:102-10.
10. Williams SF, Betran JD, Kaminer L, et al. A phase I-II study of bi-alkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 1987;5:260-5.
11. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992;19:317-32.
12. Hudis C, Lebwohl D, Yao T-J, et al. Results of sequential dose-intensive adjuvant therapy with doxorubicin and cyclophosphamide [abstr 36]. Breast Cancer Res Treatment 1994;32(suppl):37.
13. Holmes F, Walters R, Theriault R, et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
14. Seidman A, Reichman B, Crown J, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response J Clin Oncol 1995;13:1152-9.
15. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-99.
16. Hudis C, Seidman A, Baselga J, et al. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 1995;6(suppl 15):18-23.